Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00278343 · ClinicalTrials.gov registry record · Phase 2

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

A Phase 2 study of Recurrent Ovarian Epithelial Cancer and Recurrent Fallopian Tube Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
74
Enrollment target
20
Study locations

NCT00278343: Completed Phase 2 study of Recurrent Ovarian Epithelial Cancer and Recurrent Fallopian Tube Cancer, sponsored by National Cancer Institute (NCI).

NCT00278343 is a Phase 2 study of Recurrent Ovarian Epithelial Cancer and Recurrent Fallopian Tube Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 74 participants, above the 44-participant average among 14 other Recurrent Ovarian Epithelial Cancer trials with a reported enrollment target (68% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00278343, a Phase 2 study of Recurrent Ovarian Epithelial Cancer and Recurrent Fallopian Tube Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
74 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial is studying how well cediranib maleate works in treating patients with persistent, recurrent, or refractory advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer. Cediranib maleate may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

Primary Outcome

Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>= 30% decrease in the sum of the longest diameter of target lesions; Overall Response(OR) = CR+PR

Conditions Studied

Recurrent Ovarian Epithelial Cancer Recurrent Fallopian Tube Cancer Recurrent Primary Peritoneal Cavity Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG cediranib maleate

Study Locations (20)

Illinois

  • University of Chicago - Chicago
  • Decatur Memorial Hospital - Decatur
  • Evanston Hospital CCOP - Evanston
  • Ingalls Memorial Hospital - Harvey
  • Joliet Oncology-Hematology Associates Limited - Joliet
  • Loyola University Medical Center - Maywood
  • Peoria Gynecologic Oncology - Peoria
  • Oncology/Hematology Associates - Peoria
  • Central Illinois Hematology Oncology Center - Springfield

California

  • City of Hope - Duarte
  • University of Southern California/Norris Cancer Center - Los Angeles
  • City of Hope Medical Group Inc - Pasadena
  • University of California at Davis Cancer Center - Sacramento

Indiana

  • Fort Wayne Medical Oncology and Hematology Inc-Parkview - Fort Wayne
  • Northern Indiana Cancer Research Consortium - South Bend

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor
  • Oncology Care Associates PLLC - Saint Joseph

Maryland

  • University of Maryland/Greenebaum Cancer Center - Baltimore

Missouri

  • Saint John's Mercy Medical Center - St Louis

Pennsylvania

  • University of Pittsburgh Cancer Institute - Pittsburgh

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2006-04
Est. Completion 2018-01-15
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00278343 record still lists

NCT00278343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, above the 44-participant average among 14 other Recurrent Ovarian Epithelial Cancer trials with a reported enrollment target (68% higher).

The record links to 3 conditions, with Recurrent Ovarian Epithelial Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.

NCT00278343 names 20 study sites across 7 states, led by Illinois, California, Indiana.

Frequently Asked Questions

What is clinical trial NCT00278343 about?

NCT00278343 is a clinical study titled "Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer". This phase II trial is studying how well cediranib maleate works in treating patients with persistent, recurrent, or refractory advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer. Cediranib maleate may stop the growth of tumor cells by blocking blood flow to the tumor and by bl...

What is the current status of trial NCT00278343?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2006-04. Estimated completion is 2018-01-15.

What conditions does trial NCT00278343 study?

This clinical trial studies the following conditions: Recurrent Ovarian Epithelial Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cavity Cancer.

What interventions are being tested in trial NCT00278343?

The interventions under investigation include: laboratory biomarker analysis (OTHER), cediranib maleate (DRUG).

Who is sponsoring clinical trial NCT00278343?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00278343 being conducted?

This trial has 20 study locations across California, Illinois, Indiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Ovarian Epithelial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00278343's enrollment target sits among peer trials

74 2nd of 14 the highest of 14 other Recurrent Ovarian Epithelial Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Recurrent Ovarian Epithelial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00278343, the US trial registry maintained by the National Library of Medicine. NCT00278343 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.